tianeptine
Trade name: Stablon
Small moleculeexperimental
Tianeptine, sold under the brand names Stablon, Tatinol, and Coaxil among others, is an atypical tricyclic antidepressant which is used mainly in the treatment of major depressive disorder, although it may also be used to treat anxiety, asthma, and irritable bowel syndrome. — Wikipedia
Clinical trial activity
9 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
2
Earliest trial started Mar 1, 2009 (NCT00879372)
Timeline
Indications
Approved for
Mechanism of action
- glutamateMODULATOR
glutamate modulator
Chemistry & pharmacology
Loading structure…
SMILES
CN1c2ccccc2C(NCCCCCCC(=O)O)c2ccc(Cl)cc2S1(=O)=O- Mol. weight
- 436.96 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTianeptine ↗
- ChEMBLCHEMBL1289110 ↗
Also known as
- (3-chloro-6-methyl-5,5-dioxo-6,11-dihydrodibenzo(c,f)(1,2)thiazepin-11-yl)-7-aminoheptanoic acid
- ardix brand of tianeptine, monosodium salt
- coaxil
- coaxil
- jnj-39823277
- stablon
- stablon
- tianeptine
- tianeptine
- tianeptine
- tianeptine
- tianeptine
- tianeptine
- tianeptine
- tianeptine, (+-)-isomer
- tianeptine monosodium
- tianeptine monosodium
- tianeptine monosodium
- tianeptine monosodium
- tianeptine monosodium
- tianeptine, monosodium salt
- tianeptine, monosodium salt, (+-)-isomer
- tianeptine sodium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05935059 | N/A | Jun 21, 2023 | Cairo University, National Cancer Institute, Egypt |
| NCT05686408 | Phase 2 | Mar 2, 2023 | Rho, Inc., Tonix Pharmaceuticals |
| NCT06012552 | Phase 2 | Feb 17, 2023 | ABM Industries |
| NCT04249596 | Phase 4 | Mar 1, 2020 | Columbia University, Icahn School of Medicine at Mount Sinai |
| NCT04145076 | N/A | Dec 15, 2014 | University of London |
| NCT01309776 | Phase 4 | Mar 1, 2011 | Sungkyunkwan University |
| NCT02103985 | Phase 1 | May 1, 2009 | Johnson and Johnson |
| NCT02049697 | Phase 1 | Apr 1, 2009 | Johnson and Johnson |
| NCT00879372 | Phase 3 | Mar 1, 2009 | Conselho Nacional de Desenvolvimento Científico e Tecnológico, Federal University of Rio Grande do Sul, Stanley Medical Research Institute |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 2 | 2 | 1 | 2009 |
| ABM Industries | For profit | 1 | 0 | 1 | 2023 |
| Cairo University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Conselho Nacional de Desenvolvimento Científico e Tecnológico | Government | 1 | 0 | 1 | 2009 |
| Federal University of Rio Grande do Sul | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2020 |
| National Cancer Institute, Egypt | Government | 1 | 1 | 1 | 2023 |
| Rho, Inc. | For profit | 1 | 0 | 1 | 2023 |
| Stanley Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Sungkyunkwan University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Tonix Pharmaceuticals | For profit | 1 | 1 | 1 | 2023 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2014 |
13 organizations
Page 1 / 1